P23 - Boy with severe atopic dermatitis treated with omalizumab
نویسندگان
چکیده
Case report Our patient is a boy 9.5 years old who has AD, vernal conjunctivitis, persistent rhinitis and asthma and is sensitized mainly to dust mites. His AD exists since infancy but became more intense since 3 years old. In 2010 he used intense moisturizing treatment and high-potency topical corticosteroids both pro actively and on demand and under these conditions his SCORAD levels were 21-32%. In the beginning of 2011 he had a persistent deterioration (SCORAD 46%) despite intense treatment. He even required admission. On May 2011 oint tacrolimus 0.1% was also started on a daily basis with only a minor improvement (SCORAD 32%). Parents were hesitant to start systemic therapy with cyclosporine and under these circumstances consultation was given from Peadiatric Allergy Unit in Athens Paediatric Hospital A. and P. Kyriakou to start with omalizumab 750mg subcutaneously monthly. He started treatment in July 2011 and since then his condition improved dramatically. His SCORAD levels fell under 10% and gradually he also limited the use of corticosteroids and tacrolimus. Last season he stopped totally tacrolimus and stayed stable. His asthma is mainly viral induced and although under treatment with omalizumab and inhaled fluticasone he still had 3 mild episode between Sep 2011-May 2012. He stopped fluticasone in July 2012 and since then he has no episode. He is also free of symptoms between episodes with normal spirometry. His rhinitis remains mild persistent despite treatment. His vernal conjunctivitis started in 2010, was severe persistent but it is under control since 2012.
منابع مشابه
Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy
OBJECTIVE Anti IgE treatment with omalizumab is efficacious in the treatment of patients suffering from allergic asthma, improving asthma control and improving quality of life. Furthermore, this approach could be beneficial for patients with concomitant atopic dermatitis. We assessed quality of life and asthma control in atopic patients with allergic asthma and concomitant atopic dermatitis ver...
متن کاملOmalizumab treatment in severe adult atopic dermatitis.
Atopic dermatitis (AD) is one of the most common chronic skin diseases. Treatment options include lubricants, antihistamines, and corticosteroids in either topical or oral forms. Severe AD is frequently recalcitrant to these medications. We reported three cases of severe AD patients who had elevated of IgE levels and failed to response to several prior medical treatment. After being treated wit...
متن کاملThe dynamics of the manifestations of atopic dermatitis in severe persistent uncontrolled asthma children with omalizumab therapy
Background in children with severe persistent uncontrolled asthma atopic dermatitis (AD) is often characterized by persistent continually relapsing. According to the approach ICON for children > 6 y o with severe uncontrolled asthma as an additional treatment from 3-4 step of therapy omalizumab (Omab) is recommended for use of. We report on the experience of the use of Omab in children with ast...
متن کاملOmalizumab for the treatment of atopic dermatitis.
Atopy is almost always associated with an elevated immunoglobulin (Ig) E production. Omalizumab is a monoclonal anti-IgE antibody that is currently indicated for the treatment of cases of asthma that satisfy certain criteria. A number of studies have been published on the usefulness of omalizumab in the treatment of atopic dermatitis, and the results have been variable. We present our experienc...
متن کاملmalizumab for the Treatment of Atopic Dermatitis
Atopy is almost always associated with an elevated immunoglobulin (Ig) E production. Omalizumab is a monoclonal anti-IgE antibody that is currently indicated for the treatment of cases of asthma that satisfy certain criteria. A number of studies have been published on the usefulness of omalizumab in the treatment of atopic dermatitis, and the results have been variable. We present our experienc...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2014